MDGL Earnings Madrigal Pharmaceuticals, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–20 of 20
| Q1 2026 | 2026-03-31 | -3.25 | 2026-05-06 | 10-Q |
| Q1 2026 | 2025-12-31 | -10.15 | 2026-05-06 | 10-Q |
| Q1 2026 | 2025-09-30 | -8.12 | 2026-05-06 | 10-Q |
| Q1 2026 | 2025-06-30 | -4.10 | 2026-05-06 | 10-Q |
| Q1 2026 | 2025-03-31 | -2.61 | 2026-05-06 | 10-Q |
| Q1 2026 | 2024-12-31 | -17.31 | 2026-05-06 | 10-Q |
| Q3 2025 | 2024-09-30 | -19.31 | 2025-11-04 | 10-Q |
| Q2 2025 | 2024-06-30 | -14.47 | 2025-08-05 | 10-Q |
| Q1 2025 | 2024-03-31 | -7.38 | 2025-05-01 | 10-Q |
| Q1 2026 | 2023-12-31 | -17.33 | 2026-05-06 | 10-Q |
| Q3 2024 | 2023-09-30 | -14.27 | 2024-10-31 | 10-Q |
| Q2 2024 | 2023-06-30 | -8.91 | 2024-08-07 | 10-Q |
| Q1 2024 | 2023-03-31 | -4.23 | 2024-05-07 | 10-Q |
| FY 2024 | 2022-12-31 | -17.23 | 2025-02-26 | 10-K |
| FY 2023 | 2022-09-30 | -4.75 | 2024-02-28 | 10-K |
| FY 2023 | 2022-06-30 | -4.14 | 2024-02-28 | 10-K |
| FY 2023 | 2022-03-31 | -3.36 | 2024-02-28 | 10-K |
| FY 2023 | 2021-12-31 | -14.63 | 2024-02-28 | 10-K |
| FY 2022 | 2021-09-30 | -3.79 | 2023-02-23 | 10-K |
| FY 2022 | 2021-06-30 | -3.72 | 2023-02-23 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.